Rochester, NY 7/30/2009 2:12:09 AM
Antigenics Inc. AGEN, Antigenics Approve as Cancer Vaccine Shows Promise
Antigenics Inc. AGEN
Antigenics Inc. reach its highest stocks gaining almost quadruple in the last three months on hopes that it will finally be able to win regulatory approval for a kidney-cancer vaccine.
http://WhisperFromWallStreet.com offers daily stock alerts to subscribers. Scroll to bottom of page to sign up for our free alerts newsletter.
To reach its goal, the scrappy little biotech still faces some unusual twists and turns in the road ahead.
About Antigenics
Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease.
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert.
Scroll to the bottom of this page to sign up for our FREE stock alerts newsletter at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither WhisperFromWallStreet, nor any of its affiliates are registered investment advisors or broker dealers.
